Exane Derivatives’s Amedisys AMED Stock Holding History

Exane Derivatives’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	-$861	–	781
2022 Q1	$861	Hold	5	–	–	﹤0.01%	813
2021 Q4	$809	Sell	5 -259	-98%	-$41.6K	﹤0.01%	728
2021 Q3	$39.4K	Sell	264 -3,361	-93%	-$699K	0.01%	643
2021 Q2	$958K	Buy	+3,625	New	+$951K	0.22%	97
2021 Q1	–	Sell	-903	Closed	-$265K	–	904
2020 Q4	$265K	Buy	903 +539	+148%	+$138K	0.08%	264
2020 Q3	$86.1K	Buy	+364	New	+$82.8K	0.02%	326

Other funds holding AMED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Exane Derivatives's AMED Position: Q2 2022 in Review

Exane Derivatives sold out of Amedisys (AMED) in Q2 2022, closing a stake of 5 shares — an estimated $861 sold.

Exane Derivatives first reported a position in AMED in Q3 2020 and held it in 6 quarters. The position peaked at $958K in Q2 2021. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

Exane Derivatives reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 5 Amedisys shares in Q2 2022, an estimated $861.
Exane Derivatives first reported a position in Amedisys in Q3 2020 and held it in 6 quarters.
Exane Derivatives's Amedisys position peaked at $958K in Q2 2021.
288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.